<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01276626</url>
  </required_header>
  <id_info>
    <org_study_id>Nestle 09.25.NRC</org_study_id>
    <nct_id>NCT01276626</nct_id>
  </id_info>
  <brief_title>Study of Bacteria on Mood and Bowel Symptoms in Patients With Irritable Bowel Syndrome</brief_title>
  <official_title>Pilot Study of Probiotic Bifidobacterium Longum (B. Longum) on Mood and Bowel Symptoms in Patients With Irritable Bowel Syndrome (IBS).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether probiotic bacterium Bifidobacterium longum
      (B. longum) can improve mood and bowel symptoms in patients with Irritable bowel syndrome
      (IBS). The patients will be treated with probiotic or placebo for 6 weeks. Their mood,
      memory, general well-being and bowel symptoms will be assessed before, at the end of the
      treatment and 4 weeks later. Brain activation pattern, changes in gut bacteria, metabolic
      profile and inflammatory markers will be also measured.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital Anxiety and Depression (HAD) scale.</measure>
    <time_frame>6 weeks post-treatment initiation</time_frame>
    <description>Change in anxiety and depression, assessed using Hospital Anxiety and Depression (HAD) scale, after six weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in IBS symptoms.</measure>
    <time_frame>6 and 10 weeks post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in objective biomarkers.</measure>
    <time_frame>6 weeks post-treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <condition>IBS</condition>
  <arm_group>
    <arm_group_label>Bifidobacterium longum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Maltodextrin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bifidobacterium longum</intervention_name>
    <description>Powder containing Bifidobacterium longum in maltodextrin.</description>
    <arm_group_label>Bifidobacterium longum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>Powder containing only maltodextrin</description>
    <arm_group_label>Maltodextrin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Irritable Bowel Syndrome based on Rome III Criteria

          -  Symptoms of mild to moderate anxiety and depression

        Exclusion Criteria:

          -  Concurrent systemic disease and/or laboratory abnormalities considered by
             Investigators to be risky or that could interfere with data collection.

          -  Concurrent organic Gastrointestinal (GI) pathology other than benign polyps,
             diverticulosis, hemorrhoids, lipomas and melanosis coli.

          -  Psychiatric diagnosis other than anxiety or depression.

          -  Patients treated with therapeutic/standard doses of antidepressants and/or anxiolytics

          -  History of active cancer in the last 5 years, other than skin basal cells cancer

          -  Pregnant or breastfeeding women

          -  Treatment with antibiotics during the three months prior the study.

          -  Known or suspected allergies to the study products (eg maltodextrin).

          -  Patients who have heart pacemakers, metal implants, metal chips or clips in or around
             the eyeballs, artificial heart valves, metallic ear implants, bullet fragments or
             fixed brackets.

          -  High fiber diet (&gt;35 g/day for males, &gt; 25 g/day for females), consumption of high
             inulin containing foods (&gt;5 g/day).

          -  Consumption of any type of yoghurts or probiotic-containing products in the 4 weeks
             prior to the beginning of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter McLean, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Nestlé</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Premysl Bercik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McMaster University Medical Center</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2010</study_first_submitted>
  <study_first_submitted_qc>January 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2011</study_first_posted>
  <last_update_submitted>August 4, 2014</last_update_submitted>
  <last_update_submitted_qc>August 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulfalene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

